Literature DB >> 21734778

Inflammatory bowel disease in travelers: choosing the right vaccines and check-ups.

Maria Esteve1, Carme Loras, Ester García-Planella.   

Abstract

The majority of patients with inflammatory bowel disease (IBD) achieve good control of the inflammatory activity using available therapies. When remission is achieved and quality of life recovered, a considerable proportion of IBD patients express their desire to travel abroad, be it for business, academic or leisure purposes. Their physicians should help and encourage them whenever possible. However, preventive measures are warranted to minimize the risk, since IBD patients are exposed to the same infections affecting the general population, plus opportunistic infections (OI) related to the immunosuppression. There are a large number of potential OI that might affect patients with IBD. The true prevalence of these infections is unknown, and can vary from country to country. Therefore, reactivation or de novo acquisition of infections such as tuberculosis, malaria, and viral hepatitis will be much more frequent in endemic areas. Therefore, physicians should be aware of these aspects when planning specific preventive measures for patients traveling to a particular country. This includes good control of environmental exposure, chemoprophylaxis when indicated, and the use of a specific vaccination program to prevent endemic infections. In addition, it should be noted that, though the risk of acquiring an infectious disease is probably greater for IBD patients traveling from a developed to a developing country, the inverse situation can also occur; it depends on the previous acquired immunity of the host against infections in any particular environment.

Entities:  

Keywords:  Inflammatory bowel disease; Opportunistic infections; Vaccination

Mesh:

Substances:

Year:  2011        PMID: 21734778      PMCID: PMC3122259          DOI: 10.3748/wjg.v17.i22.2708

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents.

Authors:  Jose Domínguez; Irene Latorre
Journal:  J Crohns Colitis       Date:  2008-07-07       Impact factor: 9.071

Review 2.  Expert review of the evidence base for self-therapy of travelers' diarrhea.

Authors:  Herbert L DuPont; Charles D Ericsson; Michael J G Farthing; Sherwood Gorbach; Larry K Pickering; Lars Rombo; Robert Steffen; Thomas Weinke
Journal:  J Travel Med       Date:  2009-03-19       Impact factor: 8.490

Review 3.  Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

Authors:  Alan D T Barrett; Dirk E Teuwen
Journal:  Curr Opin Immunol       Date:  2009-06-10       Impact factor: 7.486

4.  World Influenza Congress Europe 2009.

Authors:  Nigel J Silman
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.217

5.  Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.

Authors:  Michael Bröker; Keith Veitch
Journal:  Travel Med Infect Dis       Date:  2010-01-08       Impact factor: 6.211

Review 6.  Rabies as a traveler's risk, especially in high-endemicity areas.

Authors:  François-Xavier Meslin
Journal:  J Travel Med       Date:  2005-04       Impact factor: 8.490

Review 7.  Contribution of PCR-based methods to diagnosis and management of imported malaria.

Authors:  A Berry; R Fabre; F Benoit-Vical; S Cassaing; J F Magnaval
Journal:  Med Trop (Mars)       Date:  2005

Review 8.  How do we manage vaccinations in patients with inflammatory bowel disease?

Authors:  Maria Esteve Comas; Carme Loras Alastruey; Fernando Fernandez-Bañares
Journal:  Dig Dis       Date:  2009-09-24       Impact factor: 2.404

Review 9.  Expert review of the evidence base for prevention of travelers' diarrhea.

Authors:  Herbert L DuPont; Charles D Ericsson; Michael J G Farthing; Sherwood Gorbach; Larry K Pickering; Lars Rombo; Robert Steffen; Thomas Weinke
Journal:  J Travel Med       Date:  2009-03-19       Impact factor: 8.490

Review 10.  Mosquitoes and mosquito repellents: a clinician's guide.

Authors:  M S Fradin
Journal:  Ann Intern Med       Date:  1998-06-01       Impact factor: 25.391

View more
  6 in total

1.  Inflammatory Bowel Disease in Travelers.

Authors:  Gerhard Rogler
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-06

Review 2.  Vaccines and recommendations for their use in inflammatory bowel disease.

Authors:  María Dolores Sánchez-Tembleque; Carmen Corella; Jose L Pérez-Calle
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

3.  Travel health and pretravel preparation in the patient with inflammatory bowel disease.

Authors:  Kay Greveson; Thomas Shepherd; John P Mulligan; Mark Hamilton; Sue Woodward; Christine Norton; Charles Murray
Journal:  Frontline Gastroenterol       Date:  2015-04-22

Review 4.  Efficacy of the vaccination in inflammatory bowel disease.

Authors:  Elisa Carrera; Rebeca Manzano; Elena Garrido
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 5.  Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?

Authors:  Jason S Reich; Francis A Farraye; Sharmeel K Wasan
Journal:  Dig Dis Sci       Date:  2016-04-09       Impact factor: 3.199

6.  Prevention of infection caused by immunosuppressive drugs in gastroenterology.

Authors:  Katarzyna Orlicka; Eleanor Barnes; Emma L Culver
Journal:  Ther Adv Chronic Dis       Date:  2013-07       Impact factor: 5.091

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.